Genmab A/S (NASDAQ:GMAB) Short Interest Up 25.4% in January

Genmab A/S (NASDAQ:GMAB - Get Free Report) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 1,730,000 shares, an increase of 25.4% from the December 31st total of 1,380,000 shares. Currently, 0.3% of the shares of the company are short sold. Based on an average trading volume of 1,240,000 shares, the short-interest ratio is currently 1.4 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Sanford C. Bernstein raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, December 20th. BMO Capital Markets reaffirmed an "outperform" rating and issued a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Redburn Atlantic began coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They set a "buy" rating on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, Genmab A/S has an average rating of "Moderate Buy" and a consensus target price of $45.20.

Genmab A/S Stock Performance

Genmab A/S stock traded up $0.26 during mid-day trading on Wednesday, reaching $19.47. The company's stock had a trading volume of 1,788,423 shares, compared to its average volume of 1,558,869. Genmab A/S has a 12-month low of $19.00 and a 12-month high of $31.88. The firm's fifty day moving average price is $20.96 and its two-hundred day moving average price is $23.55. The company has a market capitalization of $12.88 billion, a P/E ratio of 18.90, a PEG ratio of 0.55 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The business had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. During the same period in the prior year, the business posted $0.47 EPS. On average, research analysts predict that Genmab A/S will post 1.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after purchasing an additional 1,051 shares in the last quarter. Cromwell Holdings LLC raised its position in Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock valued at $60,000 after purchasing an additional 2,496 shares during the last quarter. R Squared Ltd purchased a new position in Genmab A/S during the 4th quarter valued at $93,000. Blue Trust Inc. raised its stake in Genmab A/S by 892.0% in the third quarter. Blue Trust Inc. now owns 4,315 shares of the company's stock worth $108,000 after buying an additional 3,880 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in Genmab A/S by 43.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company's stock worth $113,000 after purchasing an additional 1,413 shares in the last quarter. Institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.